Telix Pharmaceuticals (ASX:TLX) has opened the 2026 fiscal year with significant momentum, reporting an 11% quarter-over-quarter increase in group revenue to US$230 million for the period ended March 31.
The performance, a 24% leap compared to the same period last year, was driven primarily by the company’s Precision Medicine portfolio.
Revenue in this segment reached US$186 million, bolstered by the expanding market presence of Illuccix and Gozellix, the latter of which saw US dose volumes climb by 5% despite challenging North American weather conditions.
Based on these strong results, the company has reaffirmed its full-year revenue guidance of US$950 million to US$970 million.
Beyond financial gains, Telix achieved critical milestones in its clinical and regulatory pipeline.
The ProstACT Global Phase 3 study for TLX591-Tx, a promising prostate cancer therapy, met its Part 1 safety and dosimetry objectives with no new safety signals reported.
Regulatory activity also intensified globally; the company resubmitted its New Drug Application for the brain cancer imaging agent Pixclara to the US FDA while simultaneously filing for marketing authorisation in Europe under the brand name Pixlumi.
The NDA for TLX591-Px was accepted for review in China.
CEO Dr Christian Behrenbruch characterised the quarter as a period of accelerated growth and disciplined execution.
At the time of reporting, Telix Pharmaceuticals’ share price was $13.63.